A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia

Wilms’ tumor 1 (WT1) is a promising target of new immunotherapies for acute myeloid leukemia (AML) as well as for other cancers. OCV-501 is a helper peptide derived from the WT1 protein. OCV-501 induced OCV-501-specific Type 1 T-helper (Th1) responses dose-dependently and stimulated helper activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Yukio, Sakura, Toru, Miyawaki, Shuichi, Toga, Kazuyuki, Sogo, Shinji, Heike, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489634/
https://www.ncbi.nlm.nih.gov/pubmed/28321480
http://dx.doi.org/10.1007/s00262-017-1981-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489634/
https://www.ncbi.nlm.nih.gov/pubmed/28321480
http://dx.doi.org/10.1007/s00262-017-1981-3

Ejemplares similares